ICER’s 2022 “Barriers to Fair Access Assessment” Protocol

How does ICER plan to determine whether health plans offer fair access to pharmaceuticals? I summarized their approach last year as outlined in their white paper titled “Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals.” Last month, final protocol for their “Barriers to Fair Access Assessment“. While the approach follows…

Links

“…current inflation levels are much closer to past inflation peaks than the official series would suggest.” Impact of minimum wage on health Alcohol excise tax impact on drinking. Good looking CEOs? 100m Americans have health care debt.

Economic burden of antibiotic resistance

Today, one of my studies was published. The title of the study was “Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database” This is work with co-authors Alen Marijam, Ashish V. Joshi, Fanny S. Mitrani-Gold, Katie Everson, Rifat Tuly, Peter Rosenquist, Michael Gillam & Maria Elena…

The rise of prior authorization

While many patients and physicians feel that it is increasingly difficult to get insurance to cover new treatments, a JAMA Viewpoint (Resneck 2020) demonstrates this trend numerically.  Prior authorization requirements increased from 8% to approximately 24% of covered drugs on Medicare Part D plans between 2007 and 2019.1 In 4 therapeutic classes (including antidepressants, autoimmune disease…